Enzalutamide
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Enzalutamide |
| DrugBank ID | DB08899 |
| Brand Names (EU) | Enzalutamide Accordpharma, Xtandi |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.71% |
Approved Indication (EMA)
Treatment of prostate cancer.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | prostate cancer/brain cancer susceptibility | 99.71% | DL |
| 2 | prostate leiomyoma | 99.57% | DL |
| 3 | Brenner tumor | 99.55% | DL |
| 4 | fibroma of prostate | 99.53% | DL |
| 5 | benign reproductive system neoplasm | 99.53% | DL |
| 6 | male reproductive organ cancer | 99.51% | DL |
| 7 | benign prostate phyllodes tumor | 99.48% | DL |
| 8 | prostate cancer | 98.50% | DL |
| 9 | benign neoplasm of prostate | 98.37% | DL |
| 10 | prostate neoplasm | 98.37% | DL |
| 11 | prostate phyllodes tumor | 98.37% | DL |
| 12 | nonpapillary renal cell carcinoma | 98.08% | DL |
| 13 | palmoplantar keratoderma-sclerodactyly syndrome | 98.05% | DL |
| 14 | female breast carcinoma | 97.53% | DL |
| 15 | renal carcinoma | 97.53% | DL |
| 16 | peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome | 97.53% | DL |
| 17 | liposarcoma | 97.30% | DL |
| 18 | renal cell carcinoma (disease) | 97.27% | DL |
| 19 | renal cell carcinoma associated with neuroblastoma | 97.12% | DL |
| 20 | unclassified renal cell carcinoma | 97.12% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.